BACKGROUND:Inflammatory injury induced by microglial activation plays an important role in the occurrence and development of Parkinson’s disease (PD). However, few studies have examined the relationship between microglia and substantia nigra damage or dopaminergic neuron loss in animals with rotenone-induced PD. OBJECTIVE: To explore the relationship between activated microglia and loss of the substantia nigra, and the changes in concentration and dose of rotenone in the brain of rats with rotenone-induced PD. DESIGN, TIME AND SETTING: The neuropathological experiment was performed at the School of Traditional Chinese Medicine, Capital Medical University, China, from July 2007 to July 2008. MATERIALS: Rotenone was purchased from Sigma, USA. METHODS: The Parkinson’s model was induced by injection of a rotenone oily-emulsion (2 mg/kg daily) subcutaneously into the back of 58 male adult Wistar rats for 3-6 weeks. Another three rats served as normal controls. MAIN OUTCOME MEASURES: Neurobehavioral changes were observed and recorded following rotenone treatment. Tyrosine hydroxylase and complement receptor OX42 were separately analyzed by immunohistochemical staining within 4 weeks following stopping rotenone treatment. Rotenone content was measured using high performance liquid chromatography in the cerebellum of rats that scored 2, 4-6. RESULTS: Rotenone induced a loss of dopaminergic neurons in the substantia nigra as well as microglial activation, with increased behavior scores. Dopaminergic loss was still ongoing even when rotenone was stopped. Dopaminergic neuronal degeneration in the substantia nigra was ini- tially 6%, but was 85% at 2 weeks after scoring, and degeneration depended on activated microglia. Rotenone was detected in the cerebellum at concentrations between 78.9 μg/L and 309.6 μg/L. CONCLUSION: Nigrostriatal dopaminergic degeneration paralleled the microglial activation. Rotenone absorbed into the brain in its original form initiated pathological injury in the substantia nigra of PD rats. BACKGROUND: Inflammatory injury induced by microglial activation plays an important role in the occurrence and development of Parkinson’s disease (PD). However, few studies have examined the relationship between microglia and substantia nigra damage or dopaminergic neuron loss in animals with rotenone-induced PD. OBJECTIVE: To explore the relationship between activated microglia and loss of the substantia nigra, and the changes in concentration and dose of rotenone in the brain of rats with rotenone-induced PD. DESIGN, TIME AND SETTING: The neuropathological experiment was performed at the School of Traditional Chinese Medicine, Capital Medical University, China, from July 2007 to July 2008. MATERIALS: Rotenone was purchased from Sigma, USA. METHODS: The Parkinson’s model was induced by injection of a rotenone oily-emulsion (2 mg / kg daily) subcutaneously into the back of 58 male adult Wistar rats for 3-6 weeks. Another three rats served as normal controls. MAIN OUTCOME MEASURES: Neurobe havioral changes were observed and recorded following rotenone treatment. Tyrosine hydroxylase and complement receptor OX42 were separately analyzed by immunohistochemical staining within 4 weeks following rotary rotenone treatment. Rotenone content was measured using high performance liquid chromatography in the cerebellum of rats that scored 2, 4- 6. RESULTS: Rotenone induced a loss of dopaminergic neurons in the substantia nigra as well as microglial activation, with increased behavior scores. Dopaminergic loss was still under even when rotenone was stopped. Dopaminergic neuronal degeneration in the substantia nigra was ini- tially 6% , but was 85% at 2 weeks after scoring and degeneration of the activated microglia. Rotenone was detected in the cerebellum for concentrations between 78.9 μg / L and 309.6 μg / L. CONCLUSION: Nigrostriatal dopaminergic degeneration paralleled the microglial activation. Rotenone absorbed into the brain in its original form = njury in the substantia nigra of PD rats.